BR112021020241A2 - Derivados de heteroarila bicíclica como inibidores de ectonucleotídeo pirofosfatase fosfodiesterase 1 - Google Patents

Derivados de heteroarila bicíclica como inibidores de ectonucleotídeo pirofosfatase fosfodiesterase 1

Info

Publication number
BR112021020241A2
BR112021020241A2 BR112021020241A BR112021020241A BR112021020241A2 BR 112021020241 A2 BR112021020241 A2 BR 112021020241A2 BR 112021020241 A BR112021020241 A BR 112021020241A BR 112021020241 A BR112021020241 A BR 112021020241A BR 112021020241 A2 BR112021020241 A2 BR 112021020241A2
Authority
BR
Brazil
Prior art keywords
bicyclic heteroaryl
inhibitors
ectonucleotide pyrophosphatase
heteroaryl derivatives
phosphodiesterase
Prior art date
Application number
BR112021020241A
Other languages
English (en)
Inventor
Klaus Klumpp
Ronald Hawley
Original Assignee
Riboscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riboscience Llc filed Critical Riboscience Llc
Publication of BR112021020241A2 publication Critical patent/BR112021020241A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a certos compostos de heteroarila bicíclica que inibem a atividade enzimática de ectonucleotídeo pirofosfatase/fosfodiesterase 1 (enpp1) e são, portanto, úteis para o tratamento de doenças e afecções moduladas, pelo menos em parte, por enpp1. em algumas modalidades, os compostos de heteroarila bicíclica incluem aqueles de fórmula (i). são também fornecidas no presente documento composições farmacêuticas contendo tais compostos e processos para preparar tais compostos. (i)
BR112021020241A 2019-04-12 2020-04-10 Derivados de heteroarila bicíclica como inibidores de ectonucleotídeo pirofosfatase fosfodiesterase 1 BR112021020241A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833455P 2019-04-12 2019-04-12
US201962881111P 2019-07-31 2019-07-31
PCT/US2020/027700 WO2020210649A1 (en) 2019-04-12 2020-04-10 Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors

Publications (1)

Publication Number Publication Date
BR112021020241A2 true BR112021020241A2 (pt) 2021-12-07

Family

ID=70465561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020241A BR112021020241A2 (pt) 2019-04-12 2020-04-10 Derivados de heteroarila bicíclica como inibidores de ectonucleotídeo pirofosfatase fosfodiesterase 1

Country Status (23)

Country Link
US (1) US12029744B2 (pt)
EP (2) EP4249070A3 (pt)
JP (1) JP2022526432A (pt)
KR (1) KR20210151873A (pt)
CN (1) CN114040915A (pt)
AU (1) AU2020272034A1 (pt)
BR (1) BR112021020241A2 (pt)
CA (1) CA3136443A1 (pt)
DK (1) DK3952995T3 (pt)
ES (1) ES2960987T3 (pt)
FI (1) FI3952995T3 (pt)
HR (1) HRP20231413T1 (pt)
HU (1) HUE064377T2 (pt)
IL (1) IL286966A (pt)
LT (1) LT3952995T (pt)
MX (2) MX2021012305A (pt)
PL (1) PL3952995T3 (pt)
PT (1) PT3952995T (pt)
RS (1) RS64792B1 (pt)
SG (1) SG11202110888QA (pt)
SI (1) SI3952995T1 (pt)
TW (1) TW202103708A (pt)
WO (1) WO2020210649A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3200318A1 (en) * 2020-10-30 2022-05-05 1Cbio, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof
AU2022211957B2 (en) * 2021-01-29 2024-05-23 Txinno Bioscience Inc. Novel benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof
US20240209005A1 (en) * 2021-03-16 2024-06-27 Riboscience Llc Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
CN116444544A (zh) * 2022-01-10 2023-07-18 中国科学院上海药物研究所 苯并咪唑类化合物及其医药用途
WO2024099907A1 (en) * 2022-11-09 2024-05-16 Boehringer Ingelheim International Gmbh Cyclic benzimidazole derivatives as cgas inhibitors
WO2024149239A1 (zh) * 2023-01-10 2024-07-18 上海翊维康医药有限责任公司 杂芳环化合物及其制备方法和用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5240938A (en) 1991-02-13 1993-08-31 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring
GB9020931D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
IE914572A1 (en) 1991-01-17 1992-07-29 Zeneca Ltd Chemical process
IE914573A1 (en) 1991-01-17 1992-07-29 Ici Plc Boron compounds
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
US5468757A (en) 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
AU2583901A (en) 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2003000187A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
JP2005089334A (ja) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20090264384A1 (en) 2004-11-01 2009-10-22 Nuada, Inc. Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
DE102004060699A1 (de) 2004-12-16 2006-06-22 Ratiopharm Gmbh Verfahren zur Herstellung von Candesartan
PT1833801E (pt) 2004-12-22 2008-08-25 Algry Quimica S L Compostos intermediários para a preparação de antagonistas do receptor da angiotensina ii
ITMI20050801A1 (it) 2005-05-03 2006-11-04 Dipharma Spa Procedimento per la preparazione di telmisartan
WO2006125592A2 (en) * 2005-05-24 2006-11-30 Lek Pharmaceuticals D.D. Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl)methyl)-imidazole, dihydroimidazole or benzimidazole derivatives
US8071609B2 (en) 2005-08-11 2011-12-06 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
CN100427488C (zh) * 2005-10-21 2008-10-22 上海东升新材料有限公司 腺嘌呤类衍生物及其合成方法
WO2007081755A2 (en) 2006-01-09 2007-07-19 Metabasis Therapeutics, Inc. Indole-benzimidazole and indazole inhibitors of tyrosine phosphatases
AU2007269557B2 (en) 2006-07-07 2013-11-07 Gilead Sciences, Inc. Modulators of toll-like receptor 7
JP2009242240A (ja) 2006-08-04 2009-10-22 Mebiopharm Co Ltd 含ホウ素キナゾリン誘導体
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
JP2011506459A (ja) 2007-12-11 2011-03-03 セラヴァンス， インコーポレーテッド 抗高血圧剤としての二重作用性ベンゾイミダゾール誘導体およびその使用
RU2547441C2 (ru) * 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
PT2565191E (pt) 2008-05-14 2014-12-04 Astellas Pharma Inc Derivados do ácido 4-(indol-7- ilcarbonilaminometil)ciclo-hexanocarboxílico como antagonistas de receptores ep4, úteis no tratamento de insuficiência renal crónica ou de nefropatia diabética
US20100016609A1 (en) 2008-07-15 2010-01-21 Wyeth Methods for the preparation of azole compounds
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
WO2011053247A1 (en) 2009-10-29 2011-05-05 Agency For Science, Technology And Research Method for the detection of an analyte by surface enhanced raman spectroscopy (sers)
ES2559209T3 (es) 2010-04-14 2016-02-11 Bristol-Myers Squibb Company Nuevos activadores de la glucocinasa y métodos de uso de los mismos
LT2558577T (lt) 2010-04-16 2019-03-12 Nuevolution A/S Bifunkciniai kompleksai ir tokių kompleksų gamybos ir naudojimo būdai
EP2670733B1 (en) 2011-02-01 2019-04-10 The Board of Trustees of the University of Illionis N-hydroxybenzamide derivatives as hdac inhibitors and therapeutic methods using the same
MX2013013331A (es) * 2011-05-17 2014-10-17 Principia Biopharma Inc Derivados de azaindol como inhibidores de tirosina-cinasas.
PT2776439T (pt) 2011-11-09 2018-11-02 Janssen Sciences Ireland Uc Derivados de purina para o tratamento de infeções virais
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
MX362341B (es) 2014-05-01 2019-01-11 Novartis Ag Compuestos y composiciones como agonistas del receptor tipo toll 7.
US10488418B2 (en) 2014-09-02 2019-11-26 The Regents Of The University Of California Fluorescence assay for intestinal permeability
CA2963772A1 (en) 2014-10-08 2016-04-14 Thomas Helledays Stiftelse For Medicinsk Forskning Heterocyclic compounds as dctpp1 modulators
WO2016200840A1 (en) 2015-06-08 2016-12-15 Cleave Biosciences, Inc. Mono and bicyclic ring boronic acid, ester and salt compounds as inhibitors of p97 complex
AU2016304408B2 (en) * 2015-07-31 2019-02-21 Pfizer Inc., 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors
AR108906A1 (es) 2016-06-29 2018-10-10 Bristol Myers Squibb Co Heterociclos de biarilmetilo
AU2017382294A1 (en) * 2016-12-22 2019-08-01 Abbvie Inc. Compositions and methods of enhancing or augmenting type I IFN production
CA3047589A1 (en) 2016-12-22 2018-06-28 Mavupharma, Inc. Phosphodiesterase inhibitors and methods of microbial treatment
US10487084B2 (en) * 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
BR112020004209A2 (pt) 2017-08-31 2020-09-01 Abbvie Inc. inibidores da ectonucleotide piofosfatase-phosfodiesterase 1 (enpp-1) e uso dos mesmos
PL3678668T3 (pl) 2017-09-08 2024-06-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory enpp1 i ich zastosowanie w leczeniu nowotworu
WO2019096113A1 (zh) * 2017-11-14 2019-05-23 深圳市塔吉瑞生物医药有限公司 一种氘代的含硼的化合物及药物组合物和用途
CN108409767B (zh) 2018-04-13 2020-07-10 上海泰坦科技股份有限公司 一种杂环联苯硼酸的制备方法
EP3902787A4 (en) 2018-12-28 2022-12-28 Riboscience LLC QUINAZOLINE DERIVATIVES USED AS ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 INHIBITORS
CN113677350A (zh) 2019-02-01 2021-11-19 里兰斯坦福初级大学理事会 Enpp1抑制剂和调节免疫反应的方法
WO2020191501A1 (en) 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders
CA3151277A1 (en) 2019-09-16 2021-03-25 Aten Porus Lifesciences Pvt. Ltd. 2-amino-s6-substituted thiopurine compounds as inhibitors of the enpp1 protein
CN115151253A (zh) 2019-09-23 2022-10-04 南京征祥医药有限公司 磷酸二酯酶抑制剂及用途
JP2023508978A (ja) 2019-12-23 2023-03-06 サンフォード バーナム プレビス メディカル ディスカバリー インスティテュート エクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ１（ｅｎｐｐ１）モジュレーター及びその使用
MX2022009534A (es) 2020-02-04 2022-11-14 Stingray Therapeutics Inc Inhibidores de ectonucleotido pirofosfatasa/fosfofiesterasa 1 (enpp1) y metodos de uso de los mismos.
CN115362150A (zh) 2020-04-09 2022-11-18 贝达药业股份有限公司 Enpp1抑制剂及其组合物和用途

Also Published As

Publication number Publication date
US20220362266A1 (en) 2022-11-17
HUE064377T2 (hu) 2024-03-28
EP3952995A1 (en) 2022-02-16
JP2022526432A (ja) 2022-05-24
RS64792B1 (sr) 2023-11-30
AU2020272034A1 (en) 2021-10-28
DK3952995T3 (da) 2023-10-30
TW202103708A (zh) 2021-02-01
CN114040915A (zh) 2022-02-11
PL3952995T3 (pl) 2024-03-11
IL286966A (en) 2021-12-01
SI3952995T1 (sl) 2023-12-29
CA3136443A1 (en) 2020-10-15
US12029744B2 (en) 2024-07-09
HRP20231413T1 (hr) 2024-02-16
LT3952995T (lt) 2023-11-10
MX2021012305A (es) 2021-11-12
EP3952995B1 (en) 2023-09-20
EP4249070A2 (en) 2023-09-27
FI3952995T3 (fi) 2023-10-26
PT3952995T (pt) 2023-10-25
ES2960987T3 (es) 2024-03-07
MX2023011065A (es) 2023-09-28
SG11202110888QA (en) 2021-10-28
WO2020210649A1 (en) 2020-10-15
EP4249070A3 (en) 2024-04-17
KR20210151873A (ko) 2021-12-14

Similar Documents

Publication Publication Date Title
BR112021020241A2 (pt) Derivados de heteroarila bicíclica como inibidores de ectonucleotídeo pirofosfatase fosfodiesterase 1
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
EA202190137A1 (ru) Нафтиридиноновые соединения для применения в качестве активаторов t-клеток
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
BR112013003114A2 (pt) inibidores de tirosina quinase de bruton
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
EP4321513A3 (en) Pyrrolotriazine compounds as tam inhibitors
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
BR112015022462A2 (pt) inibidores de ido
BRPI0814065B8 (pt) derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
BR112015032664A2 (pt) composições
BR112015032595A2 (pt) inibidores de ido
BR112013026137A2 (pt) pirimidinil-pirróis substituídos ativos como inibidores da quinase
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
BR112015021999A8 (pt) inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase
BR112013018515A2 (pt) derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase
EA202190055A1 (ru) Производные пиразола в качестве ингибиторов malt1
BR112023019030A2 (pt) Derivados de fósforo como inibidores de sos1
MX2022000164A (es) Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos.
BR112023012947A2 (pt) Inibidores de lrrk2
MX370010B (es) Inhibidores de tirosina cinasa de bruton.